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Abstract Epidermal growth factor receptor (EGFR) inhibi-
tors have demonstrated efficacy in squamous cell carcinoma
of the head and neck (SCCHN). In addition to EGFR, other
ErbB family members are expressed and activated in SCCHN.
Afatinib is an ErbB family blocker that has been approved for
treating patients with EGFR-mutated nonsmall cell lung can-
cer. We sought to determine the efficacy of afatinib in preclin-
ical models and compare this to other EGFR-targeted agents.
Afatinib efficacy was characterized in a panel of ten SCCHN
cell lines and found to be most effective against cell lines
amplified for EGFR. Afatinib had lower IC50 values than did
gefitinib against the same panel. Two EGFR-amplified cell
lines that are resistant to gefitinib are sensitive to afatinib.
Cetuximab was not found to have a synergistic effect with
afatinib either in vitro or in vivo. Both afatinib and cetuximab
were effective in tumor xenograft model. Afatinib is an effec-
tive agent in SCCHN especially in models with EGFR
amplification.
Keywords Squamous cell carcinoma of the head and neck .
Afatinib . Gefitinib . Cetuximab . Epidermal growth factor
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Introduction
Epidermal growth factor receptor (EGFR) and HER2 are both
members of the ErbB tyrosine kinase receptor family which
also comprises HER3 and HER4. When stimulated by the
presence of a ligand, ErbB receptors homodimerize or
heterodimerize with other members of the family, and through
transphosphorylation, initiate intracellular signaling cascades
[1]. Although HER2 has no known ligand, it is believed to be
a preferred dimerization partner for EGFR and HER3 [2]. As
members of the ErbB family are often deregulated in a number
of malignancies [3], they have been an attractive option for
targeted therapy. EGFR is thought to be highly expressed in as
many as 90 % of the head and neck squamous cell carcinoma
(SCCHN) tumors [4], while the expression of HER2 is more
variable [5, 6].
One of the earliest agents to target the ErbB network
system was cetuximab, a chimeric monoclonal antibody to
EGFR. After demonstrating efficacy in preclinical models [7],
cetuximab earned FDA approval for locally advanced as well
as recurrent or metastatic SCCHN [8–11]. Another potential
therapeutic target is the intracellular tyrosine kinase domain of
ErbB receptors. First generation small molecule tyrosine ki-
nase inhibitors (TKIs), such as gefitinib and erlotinib, specif-
ically target the tyrosine kinase of EGFR and are approved for
clinical use in lung cancer. Gefitinib demonstrated excellent
activity in preclinical SCCHN models [12, 13]. In phase 2
trials, gefitinib had a response rate of 9–10 % in patients with
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recurrent or metastatic SCCHN [14]. Erlotinib had similarly
promising preclinical results [15] and slightly worse response
rates in clinical studies [16].
Afatinib is an irreversible TKI that targets all kinase com-
petent ErbB family members (EGFR, HER2, and HER4;
HER3 lacks essential catalytic residues and displays weak to
no activity) [17]. Early in vitro studies of afatinib in human
tumor cell lines demonstrated significant activity as well as an
increase in the proportion of cells in the sub-G0/G1 phase of
the cell cycle [18, 19]. Effective antitumor activity of afatinib
has also been shown in multiple xenograft models using
human cell line-derived xenografts and transgenic mouse
models [19, 20]. Phase I trials in patients with nonsmall cell
lung cancer (NSCLC) and other solid tumors found afatinib to
be well tolerated, with the most common adverse effects being
diarrhea, rash, fatigue, and nausea [21, 22]. Although not
designed to determine clinical response, there was a decrease
in tumor size in 50 % of patients [22]. At this point, besides
early evaluations assessing afatinib in combination with ra-
diotherapy in one single model system (FaDu) [23], no work
characterizing the effect of afatinib in a panel of SCCHN
models has been reported.
Materials and methods
Viability assays
Cell Titer Blue assays (Promega, Madison, WI) were used to
determine cell viability. Briefly, cells were seeded at 1000
cells/well on 96-well plates, incubated for 24 h in complete
media, maintained in serum-free conditions for 24 h, and
treated with afatinib or cetuximab for 72 h at 37 °C. Then,
Cell Titer Blue reagent was added to each well and incubated
for 2 h at 37 °C before 3 % SDS was added. Cell viability was
quantified by scanning absorbance at 570 nm in a microplate
reader (Bio-Tek, Winooski, VT).
Tumor xenografts treated with afatinib only or multiple
ErbB-targeting agents
Mice were allowed to adjust to conditions at least for 5 days
before they were used for experiments. They were housed in
Macrolon type III cages in groups of ten under standardized
specific pathogen-free (SPF) conditions at 21.5±1.5 °C tem-
perature and 55±10 % humidity. Standardized diet
(PROVIMI KLIBA) and autoclaved tap water were provided
ad libitum. HN5 or FaDu cells were injected into the right
flank of 6-week-old female BomTac:NMRI-Foxn1nu mice
(Taconic, Denmark). Tumor take was monitored over time,
and animals with established tumors (50–100 mm3) were
randomized to the treatment groups (n=10/group). Mice were
treated with either vehicle or afatinib, daily or every other day
or in a weekly alternating schedule (afatinib only experiment)
or with vehicle or other agents daily (multiple agent experi-
ment). Tumor volumes and body weights were recorded three
times a week, and median tumor volumes as well as change in
body weight were plotted over time.
Tumor xenografts treated with afatinib and cetuximab
HN5 and SCC25 cell line xenograft experiments were con-
ducted as previously described [24]. Briefly, female athymic
nude mice (Harlan, Indianapolis, IN) were maintained in a
pathogen-free animal facility in accordance with the
University of Chicago Animal Care and Use Committee.
Mice received standard laboratory rodent food and water as
desired. All handling procedures were conducted in a laminar
flow biosafety hood. At 6–7 weeks of age, mice were injected
subcutaneously in the right flank with HN5 or SCC35 cells.
Drug treatment was initiated when mean tumor volumes
reached 200 to 250 mm3. Mice were treated with cetuximab
at 30-mg/kg bodyweight two times per week, via i.p. injection
and/or afatinib at 12.5-mg/kg body weight once per day via
oral gavage, or equal volume of diluents (control). For tumor
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growth analysis, tumor size was measured with a vernier
caliper. Tumor volumes were calculated with the formula
V=0.52×L×W2, where L and W represent the length and
the width of the tumor (mm). The animals were monitored two
times per week for body weight and tumor volume.
Quantification of TGFA, EGFR, and AREG mRNA
expression and EGFR copy number by real-time PCR
The real-time PCR method for quantification of EGFR gene
expression and copy number has been reported previously
[25, 26].
FISH assays
FISH assay methods and analysis were previously described
[24]. Briefly, for the evaluation of the EGFR gene copy number
(GCN) alterations, dual-color FISH assays were conducted
using an LSIEGFR SpectrumOrange:CEP7SpectrumGreen
Probe mixture (Vysis/Abbott Molecular, Des Plaines, IL).
HER2 amplification was studied using the Vysis PathVysion
HER2 DNA Probe Kit according to manufacturer recommen-
dations (Abbott Molecular, Des Plaines, IL). CEP7 or CEP17
probes were used to distinguish true gene amplification from
EGFR or HER2 gene copy number gain (gene polysomy) and
alterations in number of chromosome 7 or 17 homologs. The
absolute number of each signal, the mean copy number of
signal per cell, the ratios of EGFR to CEP7 or HER2 to
CEP17, and the percentage of cells with given copy number
of each signal per cell were calculated. Cells with a gene to
chromosome signal ratio <2 were considered nonamplified,
whereas those with a ratio greater than 2.0 (or ≥15 copies of
EGFR per cells in ≥10 % of cells) were considered as having
true amplification. Cells with ratios near cutoff points were
equivocal or low amplified.
Western blotting
Western blots on cell lysates were performed as previously
described [24]. Visualization and quantification were per-
formed with Odyssey Infrared Imaging System (Li-Cor
Biosciences). Experiments were repeated at least three times.
PTEN antibody was purchased from Cell Signaling
Technology, Inc. (Danvers, MA). Actin antibodies were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Secondary goat anti-rabbit IgG IRDye anti-
body was purchased from LI-COR Biosciences (Lincoln,
NE). Secondary mouse IgM IRDye antibody was pur-
chased f rom Rockland Immunochemica ls Inc .
(Gilbertsville, PA).
Table 1 Afatinib IC50s compared to gefitinib IC50s of SCCHN cell
lines
Cell line Afatinib
IC50 (μM)
Confidence
interval
Gefitinib
IC50 (μM)
SCC25 0.0102 9.796e-005 to 1.062 5–10
HN5 0.06412 0.009348 to 0.4398 0.05–0.5
SCC58 0.3405 0.07144 to 1.623 >100
SQ20B 0.5176 0.08746 to 3.064 1–5
MSK921 1.174 0.6654 to 2.071 1–5
HN31 1.225 0.8320 to 1.805 1–5
SCC61 1.903 0.6092 to 5.942 5
SCC28 1.951 0.7886 to 4.827 >5
Detroit 562 2.485 0.9399 to 6.569 5–50
SCC35 8.008 5.645 to 11.36 100
Fig. 2 Viability of SCCHN cell lines treated with afatinib and cetuximab. Results from Cell Titer Blue assays. a SCC35, b Detroit 562, c SQ20B, d
SCC61
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Results
Sensitivity to afatinib
Cell viability of ten SCCHN cell lines grown in monolayer
cultures was determined over a range of afatinib concentrations
(Fig. 1) and compared to IC50 ranges of the same cell lines to
gefitinib (Table 1). In order to assess whether anti-proliferative
activity could be improved upon with the addition of
cetuximab, viability of cell lines with high IC50 values
(SCC35 and Detroit 562) was tested at several doses
(Fig. 2a, b). Treatment with cetuximab alone had little effect
on cell viability, even at relatively high concentrations
(100 nmol/L). The combination treatment resulted in CI values
above 1, thus demonstrating no evidence of a synergistic or
additive effect (data not shown). Treatment with afatinib and
cetuximab was tried on additional cell lines with greater sensi-
tivity to afatinib (SQ20B and SCC61) with similar results
(Fig. 2c, d).
In vivo tumor xenografts
In vivo activity of afatinib was first characterized against
FaDu cells injected into the right flank of BomTac:NMRI-
Foxn1nu mice. Treatment with afatinib at 10 mg/kg followed
two regimens. Both daily and intermittent treatment regimens
slowed tumor growth. Continuous dosing resulted in virtually
no tumor growth, while intermittent dosing saw increase in
tumor volume over time (Fig. 3a). Neither treatment regimen
at the doses used had a significant effect on body weight
(Fig. 3b).
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Fig. 3 In vivo activity of afatinib in FaDu cell line-derived xenografts.
Mice were treated daily with either vehicle (black circle) or afatinib as
described in (white triangle) or in a weekly alternating schedule (white
square). Tumor volumes and body weights were recorded three times a
week, and median tumor volumes (a) as well as change in body weight
(b) were plotted over time
Fig. 4 In vivo activity of afatinib in HN5 cell line-derived xenografts.
Mice were treated daily with either vehicle (gray), 2×100 mg/kg/day
lapatinib (turquoise), 75 mg/kg/day erlotinib (green), 50 mg/kg/day
neratinib (blue), or 15 mg/kg/day afatinib (orange) as described in
“Materials and methods.” Tumor volumes were recorded three times a
week. Median tumor volumes were plotted over time (a). On day 50,
relative tumor volume changes were recorded b
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The anti-tumor activity of afatinib and several other ErbB
targeting agents was further tested in mice bearing HN5
xenografts (Fig. 4). Daily treatment at 15 mg/kg resulted in
tumor regressions in all treated animals. Four complete re-
sponses and six responses displaying 75 % or more reduction
in tumor size compared to baseline were observed. Erlotinib,
at 75 mg/kg, was less potent and induced six regressions and
four tumors grew under treatment. Neratinib and lapatinib
induced tumor growth delay, but no regressions were
achieved.
The last set of in vivo experiments assessed the efficacy of
afatinib in combinationwith cetuximab. Afatinib (12.5mg/kg)
and cetuximab (30 mg/kg), separately and in combination,
were very effective at inhibiting in vivo tumor growth in both
the HN5 and SCC35 mouse xenograft models (Fig. 5). At the
doses tested, the combination treatment offered no advantage
to single agent administration.
PTEN expression
PTEN protein expression was examined by immunoblotting
of SCCHN cell line lysates.We found that all lines express the
protein at approximately equal levels (Fig. 6), eliminating
PTEN loss as an explanation of primary EGFR inhibitor
resistance in these lines.
EGFR and HER2 amplification
Four of our SSCHN cell lines were EGFR amplified by FISH
(Table 2, Fig. 7a and [26]). SCC58, HN5, and SQ20B exhibit
high amplification (EGFR/CEP7 ratio >7), and SCC25 ex-
hibits low amplification (EGFR/CEP7 ratio ~2). These same
four lines show a gain of EGFR mRNA copies normalized to
18 s mRNAwhile the remaining cell lines do not (Table 2 and
[26]). SCC28 cells do not show EGFR amplification (Table 2)
but have high EGFR gene polysomy (Fig. 7b).
SCC25, HN5, SCC58, SQ20B, SCC61, and SCC28 were
also tested for HER2/CEP17 FISH. No HER2 amplification
was found (Table 2 and Fig. 7c–h). SCC25, HN5, and SCC28
cells carried in average three copies of HER2 per cell due to
trisomy for chromosome 17.
Discussion
In vitro, SCCHN cell lines show a range of sensitivities to
afatinib. The four most sensitive cell lines, SCC58, SQ20B,
SCC25, and HN5, show amplification of EGFR by FISH
analysis and increased mRNA copy number by qPCR. This
suggests that afatinib is most effective in cell lines where
EGFR is amplified and possibly acts as a driver of cell growth.
EGFR gene copy numbers have not been correlated with
clinical activity of EGFR inhibitors in SCCHN; however, this
has not been tested in a prospective study. Our data presented
here and in the past [26] indicate that a prospective trial is
warranted. When afatinib IC50 values are compared to those
from gefitinib (Table 1), one sees that the order of increasing
resistance is almost identical, the exceptions being SCC25 and
SCC58, both of which are sensitive to afatinib but resistant to
gefitinib. This suggests that afatinib may be a better therapeu-
tic choice for cancers expressing high levels of EGFR and
may relate to the broader ErbB inhibitory scope of afatinib as
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Table 2 EGFR and HER2 gene copy number alterations and mRNA expression levels of SCCHN cell lines
Cell line FISH qPCR
EGFR GCN1 CEP7 GCN2 EGFR/CEP73 Interpretation TGFa/18 s AREG/18 s EGFR/18 s Interpretation
SCC58 32.94 4.3 7.7 High Ampl 2.02 9.67 17.08 Gain
SCC28 5.02 5.33 0.94 No Ampl, 0.39 1.86 1.77 Normal
HER2 GCN1 CEP17 GCN2 HER2/CEP173 Interpretation
SCC25 3.25 3.05 1.07 No Ampl,
HN5 2.88 3.9 0.74 No Ampl,
SCC58 1.87 2.87 0.65 No Ampl
SQ20B 2.06 4.20 0.49 No Ampl
SCC61 2.3 2.04 1.13 No Ampl
SCC28 2.85 2.93 0.97 No Ampl,
FISH: 1Mean copy number EGFR or HER2 per cell; 2 mean copy number of centromere enumeration probe (CEP7 or CEP17) per cell; 3 mean gene to
centromere ratio; Ampl, amplification, ≥15 copies of gene per cell in ≥10% of cells or gene to CEP ratio ≥2.0. An average of 80 (range, 50 to 180) well-
defined malignant nuclei were scored
qPCR: Mean values from three experiments were calculated relative to 18 s as control, arbitrarily set at 1. Gain, ≥7 copies of gene/18 s
A SCC58 B SCC28
C SCC25 D HN5 E SCC58
F SQ20B G SCC61 H SCC28
EGFR
CEP7
EGFR
CEP7
HER2
CEP17
HER2
CEP17
HER2
CEP17
HER2
CEP17
HER2
CEP17
HER2
CEP17
Fig. 7 EGFR and HER2 FISH. Images of metaphase and interphase
nuclei after FISH are presented. The EGFR and HER2 genes are
localized by red fluorescent signals, and chromosome 7 and 17
centromeres (CEP7 and CEP17) are localized by green fluorescent
signals. The cells were counterstained with DAPI (blue). EGFR/CEP7
staining of a SCC58 and b SCC28 cells. HER2/CEP17 staining of c
SCC25, d HN5, e SCC58, f SQ20B, g SCC61, and h SCC28
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compared to gefitinib. Because gefitinib inhibits EGFR only,
while afatinib targets EGFR, HER2, and HER4, one possibil-
ity could reside in differences due to HER2 signaling.
However, none of the four most sensitive lines show an
increased gene copy number for HER2 by FISH ruling out
amplification as a possible mechanism. HER3 has been im-
plicated as a mechanism of resistance to EGFR blockade in
SCCHN in one paper [27]. As afatinib has been shown to
block transphosphorylation of HER3 in vitro [19], it may be
able to address this potential resistance mechanism. Indeed,
afatinib activity was seen in cetuximab refractory patients in a
phase II trial [28] suggesting a lack of cross-resistance in some
instances.
PTEN expressionwas also not at play in afatinib resistance,
as expression levels were similar in all cell lines. The main
factors which could explain the differences in efficacy are the
irreversible binding mode and the anticipated tighter blockade
of the ErbB signaling network by afatinib. However, a mea-
sure of caution should be used in interpreting in vitro data, as
SCC35, which exhibited the highest IC50 to afatinib (Table 1),
was still sensitive to the drug in vivo (Fig. 5).
Gefitinib does block phosphorylation of AKT and ERK in
SCC25 and SCC58 [26, data not shown], possibly pointing to
signaling through STAT3 downstream. Elucidation of this
mechanism could point to a more specific subset of cases in
which afatinib is more effective than gefitinib. De Greve et al.
[29] showed an objective response to afatinib in three patients
with mutations in the tyrosine kinase domain of HER2 even
after other ErbB targeting treatments had failed. Afatinib may
be active in the presence of multiple genetic aberrations,
which render other TKIs ineffective.
Indeed, afatinib was more effective than lapatinib, erloti-
nib, and neratinib in the HN5 tumor xenograft experiment.
These three TKIs were only tested on one cell line, limiting
broad conclusions about mechanism. However the combina-
tion of irreversible binding mode and broad ErbB signaling
blockage is provided by afatinib alone among the TKIs tested
here.
With these experiments, we were unable to show added
benefit forcombination therapy with cetuximab in the most
resistant cell lines to afatinib. Afatinib and cetuximab were
very effective at arresting growth and decreasing tumor vol-
ume in vivo, both as single agents and in combination. In fact,
these treatments worked so well that any benefit from the
combination of drugs could not be seen.
Conclusion
Afatinib is most effective at arresting growth of SCCHN cell
lines in vitro that are amplified and/or overexpress EGFR.
Even EGFR-amplified cell lines which are resistant to gefitin-
ib respond well to afatinib treatment. Afatinib was well
tolerated in mice at the doses tested and was more effective
with continuous dosing. Afatinib was more effective than
other TKIs at arresting tumor xenograft growth, perhaps due
to a combination of irreversible binding and broad inhibition
of ErbB network signaling. Synergy between afatinib and
cetuximab could not be observed in vitro due to the poor
response to cetuximab and in vivo due to the excellent re-
sponse to both drugs.
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